Post-earnings recap
Reported
Thu, Mar 7, 2013
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Celldex Therapeutics reported a loss that was slightly worse than expected, leading to a decline in stock price by 4.64%. The lack of revenue information and guidance may raise concerns among investors about the company's future performance. The market reaction reflects uncertainty regarding their ongoing projects and overall financial health.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.27 | N/A | -6.72% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the challenges faced in the quarter. They emphasized their commitment to advancing their pipeline despite current setbacks.
Management did not provide specific guidance for future quarters.
The company is focusing on ongoing development projects.